News for Kezar Life Sciences, Inc. (KZR)

Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma.

Kezar Life Sciences, Inc. (NASDAQ:KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ETCompany...

Kezar Life Sciences (KZR) stock falls as the company announces Q4 results with mid-stage trial data for its lead asset zetomipzomib in autoimmune hepatitis. Read more here.

Kezar shares unchanged as takeover bid rejected

Kezar (KZR) stock fell 9% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and adopted a stockholders rights plan. Read more here.

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cone Biopharma (CNTB) experienced a significant stock drop of 5.47%, currently trading at $1.21 per share. The trading volume reached 777 shares, with no notabl

Shares of Saratoga Investment Corp. SAR rose sharply in today's pre-market trading after the company reported better-than-expected earnings and sales results fo...

Overview of the Recent Transaction On October 1, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) made a significant new investment in the biotechnology se

After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more

Aileron Therapeutics, Inc. (ALRN) experienced a significant stock drop of 5.15%, with shares priced at $3.46 and a trading volume of 31,420 shares. The stock's

The stock of BeyondSpring Inc. (BYSI) displayed significant volatility, with its value surging by 7.27%. The stock is currently priced at $2.36 per share, featu

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Investors are optimistic as we move into the third quarter earnings season.

On Wednesday, 311 stocks hit new 52-week lows.

Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

/PRNewswire/ -- DelveInsight's Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...

/PRNewswire/ -- The autoimmune hemolytic anemia therapeutics market has been segmented by product (corticosteroids, monoclonal antibodies, and others) and...